|By PR Newswire||
|April 11, 2014 08:01 AM EDT||
NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), The Medicines Company (NASDAQ: MDCO), Hospira, Inc. (NYSE: HSP), Horizon Pharma, Inc. (NASDAQ: HZNP), and Galectin Therapeutics Inc. (NASDAQ: GALT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Actavis plc Analyst Notes
On April 1, 2014, Actavis plc (Actavis) announced that it has acquired Silom Medical Company (Silom Medical) for approximately $100.0 million in cash. Actavis stated that the acquisition of Silom Medical immediately elevates Actavis into the top-five position in the Thai generic pharmaceutical market. The Company said that it expects the transaction to be immediately accretive to its non-GAAP earnings in 2014. "The acquisition of Silom Medical demonstrates our commitment to be a leading specialty pharmaceutical company in Southeast Asia, and will provide the combined business with an even more significant and united presence in the fast-growing Thai pharmaceutical market," said Paul Bisaro, Chairman and CEO of Actavis. He added, "Silom Medical's diverse product portfolio and fully integrated platform, when combined with Actavis' current local commercial activities and world-class global generics infrastructure, will provide consumers in Thailand with expanded access to a combined, larger portfolio of affordable medicines and the increased opportunity to benefit from products in development for the market. The larger presence in Thailand will also create a foundation for Actavis' continued expansion across the Southeast Asian region." The full analyst notes on Actavis plc are available to download free of charge at:
The Medicines Company Analyst Notes
On March 31, 2014, The Medicines Company announced that Judge Andrews in the US District Court of Delaware has issued his Trial Opinion in The Medicines Company v. Hospira, Inc. (Hospira), involving Hospira's Abbreviated New Drug Applications (ANDAs) seeking approval to commercially manufacture, use, or sell a generic version of The Medicines Company's Angiomax bivalirudin drug product before the expiration of the patents covering the product. The Company informed that with respect to patent validity, the Court held that the two patents in the case, U.S. Patent Nos. 7,582,727 and 7,598,343 were valid on all grounds; and that Hospira had failed to prove that the patents were either anticipated and/or obvious. The Medicines Company added that the Court further held that the patents satisfied the written description requirement, were enabled and were not indefinite. The Medicines Company informed that the Court has not yet entered a final judgment. The full analyst notes on The Medicines Company are available to download free of charge at:
Hospira, Inc. Analyst Notes
On March 31, 2014, Hospira, Inc. (Hospira) announced that it intends to release its Q1 2014 results on April 30, 2014, before the US stock market opens. The Company stated that on the same day, after the release, it will hold a conference call at 8:00 a.m. CT to discuss these results. Hospira added that a live webcast of the conference call and related material will be available on its website and a replay will be available at the same location for 30 days following the call. The full analyst notes on Hospira, Inc. are available to download free of charge at:
Horizon Pharma, Inc. Analyst Notes
On March 27, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced that the Compensation Committee of its Board of Directors has approved the grant of inducement stock options to purchase an aggregate of 96,750 shares of common stock to 26 new employees. The Company informed that the stock options were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4). Horizon Pharma stated that each stock option has an exercise price per share equal to $15.08 (the fair market value on the grant date) and vests over four years. The full analyst notes on Horizon Pharma, Inc. are available to download free of charge at:
Galectin Therapeutics Inc. Analyst Notes
On March 31, 2014, Galectin Therapeutics Inc. (Galectin) announced that results from the first cohort of the Company's Phase 1 trial demonstrate that GR-MD-02 had an effect on biomarkers that suggest a therapeutic effect on fibrosis, inflammation, and cellular injury. The Company informed that the first cohort results indicate that GR-MD-02 was safe and well tolerated following four doses of 2 mg/kg (80 mg/m) and there were no serious adverse events. "We are extremely pleased with the positive results of the first cohort of our Phase 1 trial, which suggest a role for GR-MD-02 in the treatment of patients with fatty liver disease with advanced fibrosis," said Peter G. Traber, M.D., CEO, President and Chief Medical Officer of Galectin. The Company stated that the second cohort is expected to begin enrolment in April 2014. The full analyst notes on Galectin Therapeutics Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Jul. 8, 2015 03:00 AM EDT Reads: 1,602
Jul. 8, 2015 03:00 AM EDT Reads: 837
Jul. 8, 2015 02:15 AM EDT Reads: 1,144
Jul. 8, 2015 12:00 AM EDT Reads: 2,550
Jul. 7, 2015 10:30 PM EDT Reads: 2,505
Jul. 7, 2015 10:15 PM EDT Reads: 1,270
Jul. 7, 2015 09:30 PM EDT Reads: 1,271
Jul. 7, 2015 08:00 PM EDT Reads: 1,034
Jul. 7, 2015 07:00 PM EDT Reads: 2,674
Jul. 7, 2015 07:00 PM EDT Reads: 2,648
Jul. 7, 2015 05:45 PM EDT Reads: 2,517
Jul. 7, 2015 05:00 PM EDT Reads: 2,334
Jul. 7, 2015 05:00 PM EDT Reads: 2,295
Jul. 7, 2015 04:45 PM EDT Reads: 1,762
Jul. 7, 2015 04:15 PM EDT Reads: 913